Drugs / RO7191863
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04225715 | Jul 2020 → Jul 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7191863 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225715 ↗ |
| Modality | Oligonucleotide (other) | “Programmed Death Ligand-1 Locked Nucleic Acid (PD-L1 LNA; RO7191863)” NCT04225715 ↗ |
| Route | Subcutaneous | “PD-L1 LNA (RO7191863) will be administered subcutaneously” NCT04225715 ↗ |